Liver function and cough drug: new study checks safety
NCT ID NCT06222892
First seen Jan 09, 2026 · Last updated May 20, 2026 · Updated 17 times
Summary
This study looked at how a new cough medicine, camlipixant, behaves in people with liver problems compared to those with healthy livers. Researchers measured drug levels in the blood and monitored safety in 32 adults aged 18 to 75. The goal was to understand if liver impairment changes how the drug is processed, which helps guide proper dosing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COUGH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Miami, Florida, 33136, United States
-
GSK Investigational Site
Orlando, Florida, 32809, United States
-
GSK Investigational Site
San Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.